Episodios
-
This podcast episode delves into the complexities of informed consent in healthcare, particularly in the context of hematology. The discussion with host Dr Charles de Bock features insights from Dr Stephen Hibbs and Dr Louise Caldwell, authors of the HemaTopics "Informed consent is almost impossible” and guest Mark Dawson, a patient family member, exploring the emotional, legal, and ethical dimensions of consent. Key themes include the variability of consent across jurisdictions, the impact of time pressures on communication, and the importance of trust in the clinician-patient relationship. The conversation also addresses the challenges posed by genetic testing and the need for ongoing discussions about consent throughout a patient's treatment journey.
“Informed consent is almost impossible”, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and our YouTube channel. Listen and enjoy casual, insightful discussions about #hematology research. Hear the stories behind the papers.
You can find the referenced article, in full and open access, on the HemaSphere website.
Publications mentioned in this podcast:
The Immortal Life of Henrietta Lacks, by Rebecca SklootThe Logic of Care: Health and the Problem of Patient Choice, by Annemarie Mol
-
In the latest episode, Dr Charles de Bock talks with Prof H. Josef Vormoor and Dr Maria Ester Bernardo, Chair and Co-Chair of EHA’s Pediatric Hematology Specialized Working Group. They discuss highlights from the EHA 2024 Congress in Madrid, including key lectures, new insights and what they could mean for clinicians, researchers, patients and their families, along with hopes and expectations for the EHA2025 Congress in Milan.
“Best of Pediatric Hematology from EHA2024”, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and our YouTube channel. Listen and enjoy casual, insightful discussions about #hematology research.
We are pleased to offer HemaSphere’s full listing of publications about pediatric hematology, now in a dedicated collection. This online collection will be added to monthly.
You can find the referenced article, in full and open access, on the HemaSphere website.
-
¿Faltan episodios?
-
Authors of this recent HemaSphere published paper discovered a high-risk subgroup of pediatric T-LBL, defined by NOTCH1 gene fusions. This finding will have an important impact on newly diagnosed children with T-LBL globally, listen to two of the co-authors, Dr Jan Loeffen and Professor Roland Kuipers discuss their findings with Dr Charles de Bock, how they discovered them, and dreams of future developments in this HemaSphere podcast episode.
NOTCH1 fusions in T‐LBL, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) including YouTube
Listen and enjoy casual, insightful discussions about #hematology research.
You can find the referenced article, in full and open access, here on the HemaSphere website.
-
In this newest podcast episode, Dr Charles de Bock hosts Dr Thomas Mercher and Dr Alexandre Fagnan. This episode is based on their recent paper, “The ETO2 transcriptional co-factor maintains acute leukemia by driving a MYB/EP300-dependent stemness program”, highlighting ETO2 activated gene transcription and how this affects erythroleukemia. The discussion traces the journey from part of Dr Fagnan’s PhD project (2022 EHA Junior Grant awardee), the findings in the paper and what may lie beyond.
This episode is also available on our YouTube channel .
Listen and enjoy casual, insightful discussions about #hematology research.
You can find the referenced article, “The ETO2 transcriptional co-factor maintains acute leukemia by driving a MYB/EP300-dependent stemness program” in full and open access, here on the HemaSphere website.
-
Welcome to Season 2 of our podcast! In this episode, Dr. Francesca Vinchi interviews Professor Alessandra Balduini about thrombopoiesis. They explore Prof. Balduini's journey into research, her intuition that led to silk scaffolding, and her hopes on future results.
"Unraveling the secrets of thrombopoiesis", is on our website and all major podcast platforms (Spotify, Apple Podcast, YouTube, etc). Listen and enjoy casual, insightful discussions about #hematology research.
You can find the referenced article, "Targeting Bone Marrow Mechanosensation in Myelofibrosis." in full and open access, here on the HemaSphere website.
-
Dr Stephen Hibbs invites HemaSphere Associate Editor Prof Robert K Hills to discuss statistics in scientific writing in an entertaining and informative episode: What’s so Great About the P-value? A Statistician’s Point of View. This discussion covers the overlap of statistics and hematology with themes like the importance of P value and the use of statistics in clinical trials.
What’s so Great About the P-value? A Statistician’s Point of View, is on our website , all major podcast platforms (Spotify, Apple Podcast, etc), and YouTube.
Listen and enjoy casual, insightful discussions about #hematology research. HemaSphere articles are always fully open access.
Recent HemaSphere articles you may find interesting:
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
Merryman R, Michaud L, Redd R, et al.
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.
Palmi C, Bresolin S, Junk S, et al.
-
Dr Stephen Hibbs invites Dr Joseph Taylor to a discussion based on Dr Hibbs popular HemaTopics article, This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies. The conversation ranges from the type of training providers receive, how to talk to patients about these bone marrow biopsies, and some of the outstanding questions about bone marrow biopsies and the patient experience.
This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies, is on our website, all major podcast platforms (Spotify, Apple Podcast, etc), and YouTube. You can find the referenced article, in full and open access, on the HemaSphere website.
Listen and enjoy casual, insightful discussions about #hematology research.
HemaTopics are HemaSphere publications written by our Scientific Editors, focusing on hot hematology topics including recent research developments, updates on diagnosis and treatment, policy and guidelines news, and more.
-
Though many advances have been made in neutropenias, diagnosis and management are still based on physicians’ experience or local practices. Prof Francesca Fioredda and Prof Helen Papadaki, two co-authors of the HemaSphere published article The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action, discuss with host Dr Stephen Hibbs the challenges and outcomes in creating a guideline for diagnosis and managing neutropenia in adults and children. Read the referenced article on the HemaSphere website and watch on YouTube.
-
POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article Comprehensive Diagnosis and Management of POEMS Syndrome offers a clinical blueprint for managing POEMS, from diagnostics to work-up, therapy selection, follow-up, and relapse treatment. Shirley d'Sa & Michael Lunn, two co-authors of the article discuss with host Dr Stephen Hibbs, in this second of two episodes, why multidisciplinary collaboration is essential.
Catch up with Part 1 here.
Read the referenced article in HemaSphere, and also watch the videos onYouTube: Part 1 https://youtu.be/TE-t-rPztJw Part 2 https://youtu.be/hBE7KShFRhI
-
POEMS syndrome (Polyneuropathy Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article, Comprehensive Diagnosis and Management of POEMS Syndrome, offers a clinical blueprint for managing POEMS, from diagnostics to work-up, therapy selection, follow-up, and relapse treatment. Shirley d'Sa & Michael Lunn, two co-authors of the article discuss with host Dr Stephen Hibbs, in this first of 2 episodes, why multidisciplinary collaboration is essential.
Continue with Part 2 here.
This podcast is also available on YouTube: Part 1 and Part 2
-
Machine Learning is a subsection in the
field of Artificial Intelligence. How can this be used as a tool in hematology-oncology for advanced disease prognostification and beyond? Adrián Mosquera-Orgueira and Juan Carlos Hernández-Boluda, two co-authors of the HemaSphere published article Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis, discuss with host Dr Stephen Hibbs the challenges and outcomes in utilizing a novel myelofibrosis survival model that aids in risk stratification for patients diagnosed with myelofibrosis. Read the referenced article in HemaSphere, also available on our YouTube channel.
-
As the overall cancer death rate has declined over past decades and cancer survival has increased, unforeseen challenges are emerging. Thrombocytopenia, often associated with cancer disease or anticancer therapy, will be more present in thrombotic cancer patients, but evidence on how to treat these patients is lacking. Prof Anna Falanga discusses these Guidelines with host Dr Stephen Hibbs in this HemaSphere Podcast episode. You can find the referenced article, in full and open access, here on the HemaSphere website, or watch the video on our YouTube channel.
-
What to do next for “Long COVID-19” of researchers? A survey from scientists to
scientists led by the Young European Hematology Association (Young EHA)committee led to
this discussion about how COVID-19 impacted researchers, especially earlier in
their career and without a network. What tools did they discover to get through
it? Find it on the HemaSphere website, “Long COVID-19” of Researchers: What to Do Next? , or watch on our YouTube channel.
